Literature DB >> 6140901

The chemotherapy of rodent malaria, XXXIV. Causal prophylaxis Part III: Ultrastructural changes induced in exo-erythrocytic schizonts of Plasmodium yoelii yoelii by primaquine.

Y Boulard, I Landau, F Miltgen, D S Ellis, W Peters.   

Abstract

Wistar rats were injected intravenously with sporozoites from Anopheles stephensi infected with Plasmodium yoelii yoelii. The animals were subsequently treated with primaquine at doses of 30, 50 or 100 mg kg-1 at various times. Liver biopsies were made and the exoerythrocytic schizonts examined by light and electron microscopy between 45 and 50 hours. The action of the drug appeared to be principally on the parasite mitochondria, the membranes of which became thickened, then proliferated into multiple layers. Finally the whole organelles swelled up losing all structural organisation. Other parasite membranes were affected similarly and the peripheral enzyme granules disappeared. Following treatment the small, disrupted schizonts were apparently absorbed by their host cells which appeared unaffected by primaquine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6140901

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  7 in total

1.  Effect of the 8-aminoquinoline primaquine on culture-derived gametocytes of the malaria parasite Plasmodium falciparum.

Authors:  H N Lanners
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

2.  Selective toxicity of the antimalarial primaquine-evidence for both uncoupling and inhibitory effects of a metabolite on the energetics of mitochondria and its ATP synthase complex.

Authors:  J K Baker; J M Hullihen; P L Pedersen
Journal:  Pharm Res       Date:  1986-10       Impact factor: 4.200

3.  Transformation of sporozoites of Plasmodium berghei into exoerythrocytic forms in the liver of its mammalian host.

Authors:  J F Meis; J P Verhave; P H Jap; J H Meuwissen
Journal:  Cell Tissue Res       Date:  1985       Impact factor: 5.249

Review 4.  New answers through chemotherapy?

Authors:  W Peters
Journal:  Experientia       Date:  1984-12-15

5.  The antimalarial drug primaquine targets Fe-S cluster proteins and yeast respiratory growth.

Authors:  Anaïs Lalève; Cindy Vallières; Marie-Pierre Golinelli-Cohen; Cécile Bouton; Zehua Song; Grzegorz Pawlik; Sarah M Tindall; Simon V Avery; Jérôme Clain; Brigitte Meunier
Journal:  Redox Biol       Date:  2015-11-26       Impact factor: 11.799

6.  Plasmodium vivax latent liver infection is characterized by persistent hypnozoites, hypnozoite-derived schizonts, and time-dependent efficacy of primaquine.

Authors:  Erika L Flannery; Niwat Kangwanrangsan; Vorada Chuenchob; Wanlapa Roobsoong; Matthew Fishbaugher; Kevin Zhou; Zachary P Billman; Thomas Martinson; Tayla M Olsen; Carola Schäfer; Brice Campo; Sean C Murphy; Sebastian A Mikolajczak; Stefan H I Kappe; Jetsumon Sattabongkot
Journal:  Mol Ther Methods Clin Dev       Date:  2022-08-02       Impact factor: 5.849

7.  A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum.

Authors:  Alison Roth; Steven P Maher; Amy J Conway; Ratawan Ubalee; Victor Chaumeau; Chiara Andolina; Stephen A Kaba; Amélie Vantaux; Malina A Bakowski; Richard Thomson-Luque; Swamy Rakesh Adapa; Naresh Singh; Samantha J Barnes; Caitlin A Cooper; Mélanie Rouillier; Case W McNamara; Sebastian A Mikolajczak; Noah Sather; Benoît Witkowski; Brice Campo; Stefan H I Kappe; David E Lanar; François Nosten; Silas Davidson; Rays H Y Jiang; Dennis E Kyle; John H Adams
Journal:  Nat Commun       Date:  2018-05-09       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.